teladoc glp-1 expands provider-based program to prediabetes, weight management as demand surges for weight loss drugs Teladoc Health Expands Obesity &

With this approach, hydrogels can easily reach the NP, which is known to be avascular and therefore difficult to reach systemically

For more insights and updates from the world of peptide research, be sure to connect with our community on our Facebook page

Ethics declarations Competing interests All authors declare no competing interests

By Type The GLP-1 receptor agonist market is segmented by drug class into: a) Liraglutide b) Semaglutide c) Tirzepatide d) Dulaglutide e) Other Drugs By Route Of Administration The GLP-1 receptor agonist market is segmented by route of administration into: a) Parenteral b) Oral By End-User The GLP-1 receptor agonist market is segmented by end-user into: a) Hospitals b) Surgical Clinics c) Other End-Users By Geography - The GLP-1 receptor agonist market is segmented by geography into: China India Japan Australia Indonesia South Korea USA Canada Brazil France Germany UK Italy Spain Russia o Asia Pacific o Africa GLP-1 Receptor Agonist Market Drivers The key drivers of the GLP-1 receptor agonist market include: Rise In Obesity Rates During the forecast period, the rise in obesity rates will propel the growth of the GLP-1 receptor agonist market